ES2193408T3 - Aplicaciones terapeuticas de antigenos o epitopos asociados con un procesamiento celular insuficiente de peptidos, por ejemplo, expresados en celulas rma-s transfectadas con un gen b7-1. - Google Patents

Aplicaciones terapeuticas de antigenos o epitopos asociados con un procesamiento celular insuficiente de peptidos, por ejemplo, expresados en celulas rma-s transfectadas con un gen b7-1.

Info

Publication number
ES2193408T3
ES2193408T3 ES97948102T ES97948102T ES2193408T3 ES 2193408 T3 ES2193408 T3 ES 2193408T3 ES 97948102 T ES97948102 T ES 97948102T ES 97948102 T ES97948102 T ES 97948102T ES 2193408 T3 ES2193408 T3 ES 2193408T3
Authority
ES
Spain
Prior art keywords
antigens
cells
peptidic
processing
epithopes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97948102T
Other languages
English (en)
Inventor
Elisabeth Wolpert
Klas Karre
Max Pettersson
Johan Sandberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ACCURO IMMUNOLOGY AB
Original Assignee
ACCURO IMMUNOLOGY AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ACCURO IMMUNOLOGY AB filed Critical ACCURO IMMUNOLOGY AB
Application granted granted Critical
Publication of ES2193408T3 publication Critical patent/ES2193408T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

LA INVENCION SE REFIERE A LA UTILIZACION DE SUSTANCIAS QUE PUEDAN INDUCIR LA EXPRESION DE ANTIGENOS O EPITOPOS ASOCIADOS CON UN PROCESAMIENTO PEPTIDICO CELULAR ALTERADO, ESPECIALMENTE DEPENDIENTE DE UN CMH DE CLASE I, PARA LA PREPARACION DE PRODUCTOS FARMACEUTICOS, COMPOSICIONES FARMACEUTICAS O VACUNAS, QUE ESTIMULEN LAS RESPUESTAS INMUNES INTERMEDIADAS POR CELULAS T ESPECIFICAS CONTRA EL CANCER Y LAS CELULAS INFECTADAS POR VIRUS. LA INVENCION TAMBIEN SE REFIERE A LA UTILIZACION DE ANTIGENOS O EPITOPOS ASOCIADOS CON UN PROCESAMIENTO PEPTIDICO CELULAR ALTERADO, ESPECIALMENTE DEPENDIENTE DEL CMH DE CLASE I, O CON UNA PARTE DEL MISMO, PARA LOS MISMOS PROPOSITOS. LA INVENCION TAMBIEN SE REFIERE A CELULAS DE MAMIFEROS QUE HAN SIDO MANIPULADAS PARA EXPRESAR ANTIGENOS O EPITOPOS ASOCIADOS CON EL PROCESAMIENTO PEPTIDICO CELULAR ALTERADO, ESPECIALMENTE DEPENDIENTE DEL CMH DE CLASE I, Y A CELULAS LINFOIDES ACTIVADAS CONTRA LAS ESTRUCTURAS DEPENDIENTES DEL CMH DE CLASE I PARA LOS MISMOS PROPOSITOS. ADEMAS, SE PRESENTAN PROCESOS PARA LA MANIPULACION DE CELULAS DE MAMIFEROS Y PARA EL TRATAMIENTO DE SERES HUMANOS ASI COMO EQUIPOS PARA SU USO EN LAS MANIPULACIONES. LA INVENCION TAMBIEN SE REFIERE A LA UTILIZACION DE MOLECULAS QUE INCLUYEN RECEPTORES DE LAS CELULAS T O PARTES DE LOS MISMOS QUE SE DIRIGEN CONTRA LOS ANTIGENOS O EPITOPOS ASOCIADOS CON EL PROCESAMIENTO PEPTIDICO CELULAR ALTERADO, ESPECIALMENTE DEPENDIENTE DEL CMH DE CLASE I, PARA LA PREPARACION DE PRODUCTOS FARMACEUTICOS, COMPOSICIONES FARMACEUTICAS O VACUNAS. DE ACUERDO CON LA INVENCION, EL PROPOSITO ULTIMO DE LOS PRODUCTOS O PROCESOS ANTERIORES EN EL TRATAMIENTO, LA PREVENCION Y LA DIAGNOSIS DE CANCERES E INFECCIONES VIRALES.
ES97948102T 1996-12-12 1997-12-12 Aplicaciones terapeuticas de antigenos o epitopos asociados con un procesamiento celular insuficiente de peptidos, por ejemplo, expresados en celulas rma-s transfectadas con un gen b7-1. Expired - Lifetime ES2193408T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9604581A SE9604581D0 (sv) 1996-12-12 1996-12-12 An agent against cancer and virus infections

Publications (1)

Publication Number Publication Date
ES2193408T3 true ES2193408T3 (es) 2003-11-01

Family

ID=20404956

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97948102T Expired - Lifetime ES2193408T3 (es) 1996-12-12 1997-12-12 Aplicaciones terapeuticas de antigenos o epitopos asociados con un procesamiento celular insuficiente de peptidos, por ejemplo, expresados en celulas rma-s transfectadas con un gen b7-1.

Country Status (12)

Country Link
US (1) US20030087846A1 (es)
EP (1) EP0964697B1 (es)
JP (1) JP2001517208A (es)
AT (1) ATE234628T1 (es)
AU (1) AU5423898A (es)
CA (1) CA2274837A1 (es)
DE (1) DE69720065T2 (es)
DK (1) DK0964697T3 (es)
ES (1) ES2193408T3 (es)
PT (1) PT964697E (es)
SE (1) SE9604581D0 (es)
WO (1) WO1998025645A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022573A2 (en) * 2000-09-15 2002-03-21 The Scripps Research Institute Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies
EP1994406A1 (en) * 2006-03-16 2008-11-26 Leiden University Medical Center Methods for identifying t-cell epitopes associated with impaired peptide processing and applications of the identified epitopes
WO2008069663A1 (en) 2006-12-07 2008-06-12 Publiekrechtelijke Rechtspersoon Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum Use of a varicellovirus tap-inhibitor for the induction of tumor- or virus-specific immunity against teipp
US9249423B2 (en) 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
WO2008097926A2 (en) * 2007-02-02 2008-08-14 Yale University Transient transfection with rna
US10155038B2 (en) 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
WO2009008713A1 (en) * 2007-07-09 2009-01-15 Publiekrechtelijke Rechtspersoon Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Ce Tap-inhibitors from old world primate 1-herpesviruses and their use
FR2931485B1 (fr) * 2008-05-23 2011-06-17 Centre Nat Rech Scient Vaccin antitumoral comprenant des cellules tumorales modifiees
WO2012089225A1 (en) 2010-12-29 2012-07-05 Curevac Gmbh Combination of vaccination and inhibition of mhc class i restricted antigen presentation
MA39818A (fr) 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
EP4096787A4 (en) * 2020-01-29 2024-05-29 University of Miami VACCINATION AGAINST ANTIGENS INDUCED IN CELLS INFECTED BY A PATHOGEN
CN111979243B (zh) * 2020-08-24 2023-05-23 大连大学 利用CRISPR/Cas9系统构建TAP基因缺失的猪T2细胞的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2024458A1 (en) * 1970-05-20 1971-12-02 Hartmann geb. Ungewitter, Philippine, Dr., 8000 München Tumour antigen - modified and potentiated by irradiation
DE2918927A1 (de) * 1979-05-10 1980-11-20 Hans Prof Dr Limburg Arzneipraeparat zur behandlung von carcinomen und verfahren zu dessen herstellung
JPH08501280A (ja) * 1992-05-26 1996-02-13 リュクスウニヴェルシテート レイデン ヒトＴ細胞応答誘発組成物に用いるためのヒトｐ５３タンパク質のペプチドおよびヒトｐ５３タンパク質特異的細胞毒性Ｔリンパ球
ES2197147T3 (es) * 1992-10-02 2004-01-01 Bristol-Myers Squibb Company Inhibicion del crecimiento de celulas tumorales mediante la administracion de celulas transfectadas b7.
US5750398A (en) * 1993-11-30 1998-05-12 David C. Johnson Vector, element and method for inhibiting immune recognition
US6361770B1 (en) * 1994-09-23 2002-03-26 University Of British Columbia Method of enhancing expression of MHC class I molecules bearing endogenous peptides
EP0863913A4 (en) * 1995-08-21 2001-04-11 Univ Duke METHOD FOR RECOVERING THE DENSITY OF ANTIGENS ON ANTIGENT PRESENTING CELLS

Also Published As

Publication number Publication date
EP0964697B1 (en) 2003-03-19
DK0964697T3 (da) 2003-04-22
CA2274837A1 (en) 1998-06-18
EP0964697A1 (en) 1999-12-22
WO1998025645A1 (en) 1998-06-18
ATE234628T1 (de) 2003-04-15
DE69720065D1 (de) 2003-04-24
JP2001517208A (ja) 2001-10-02
DE69720065T2 (de) 2003-12-04
SE9604581D0 (sv) 1996-12-12
PT964697E (pt) 2003-07-31
AU5423898A (en) 1998-07-03
US20030087846A1 (en) 2003-05-08

Similar Documents

Publication Publication Date Title
ES2193408T3 (es) Aplicaciones terapeuticas de antigenos o epitopos asociados con un procesamiento celular insuficiente de peptidos, por ejemplo, expresados en celulas rma-s transfectadas con un gen b7-1.
CO5690564A2 (es) Medicamento para tratar tejido de miocardio infartado que comprende mioblastos oseos de mamiferos geneticamente modoficados para expresar la proteina sdf-1 de mamifero
ES2083764T3 (es) Vacuna contra el sindrome respiratorio reproductivo porcino (srrp) y diagnostico.
ES2165405T3 (es) Cepas de vacuna europeas del virus del sindrome reproductor y respiratorio porcino (prrsv).
NL300365I1 (nl) Recombinante influenzavirussen voor vaccins en gentherapie
MX9202783A (es) Hepatitis c diagnostico y vacuna.
ES2104556T3 (es) Peptidos que tienen propiedades inmunologicas de hiv-2.
BR9814606A (pt) Formulação de vacina e métodos de tratamento de um indivìduo infectado com um vìrus hpv e de prevenção de infecção por papiloma vìrus
ES2126620T3 (es) Retrovirus del grupo de los vih y su utilizacion.
AR020134A1 (es) Antigenos inmunologicos contra el virus herpes simplex y metodos para el uso de los mismos
ES2070997T3 (es) Virus de herpes recombinante de pavos y vacunas vector vivas derivadas de los mismos.
CY1113689T1 (el) Εξασθενημενοι ιοι αρνητικου κλωνου με αλλοιωμενη δραστικοτητα ανταγωνισμου ιντερφερονης για χρηση ως εμβολια και φαρμακευτικα προϊοντα
DE69632235D1 (de) Newcastle-Krankheitsvirus-Kombinationsimpfstoff
Climent et al. Dendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8+ T cell responses in HIV-1-infected individuals
ES2074950B1 (es) Vacuna para la prevencion de la enfermedad reproductiva y respiratoria de la cerda.
CA2111580A1 (fr) Composes immunogenes a effet notamment anti-cytokine, procede de preparation, compositions pharmaceutiques et kits les renfermant
GB2255093A (en) Hiv-1 core protein fragments
ES2141750T3 (es) Composicion que contiene a la vez una forma soluble y una forma insoluble de un inmunogeno.
ES2137160T3 (es) Lipopeptidos inductores de los linfocitos t-citotoxicos y utilizacion como vacunas.
AR021414A1 (es) Formulaciones conteniendo particulas semejantes a virus como inmunopotenciadores por via mucosal
ES2141093T3 (es) Herpesvirus equinos (ehv) que contienen adn ajeno, procedimiento para su obtencion y su empleo en vacunas.
AR009365A1 (es) Vacunas del virus de la fiebre aftosa (fmdv), peptidos, secuencias de adn y el uso de los peptidos en sistemas de deteccion y el uso de la vacuna fmdc para la preparacion de una composicion para inmunizar cerdos y ganado vacuno
ES2144400T3 (es) Gen que codifica la gliproteina d del virus del herpes equino de tipo 1, su producto genico, anticuerpos y su utilizacion.
ES2061603T3 (es) Mutantes viricos de la rinotraqueitis bovina infecciosa, vacunas que los contienen, metodos para la produccion de los mismos y metodos para el empleo de los mismos.
ES2118242T3 (es) Vacunas anti virus de la inmunodeficiencia felina (fiv).